One of the challenges in cancer drug development is low responding rate in clinical trials. Intrinsic subtype and immunity evaluation based on gene expression profiles of tumor tissue could be new companion biomarkers for identification of sensitive individuals and help improve success rate in clinical trials for cancer drug development. 

Tests：Intrinsic subtype
      Cancer-specified immunity score
Caners available for the tests: Breast cancer, Lung adenocarcinoma, Lung squamous carcinoma, Hepatocellular cancer, colorectal cancer